All In Biotech

Drug Trial Radar · NCT00254046

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treatment to no Treatment Options.

Last checked: Nov 19, 2026Latest source record: Jun 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 616 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

616

Actual

Start

Nov 2005

Primary completion

Feb 2007

Study completion Jul 2008

Sponsor

Sponsor type
Industry
First posted
Nov 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus. The study will also investigate whether this new medication is well tolerated, and to further confirm that the medication is safe to be used.

Conditions

  • HIV

Interventions

  • TMC125Drug

    2 X100 mg tablets b.i.d.96 weeks

  • PlaceboDrug

    2 tablets b.i.d.96 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen.Time frame: 24 weeks

Locations

55 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Beverly Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami Beach, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Safety Harbor, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Vero Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    Wichita, Kansas

  • Site not named

    Boston, Massachusetts

  • Site not named

    Newark, New Jersey

  • Site not named

    Santa Fe, New Mexico

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Huntersville, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Galveston, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Longview, Texas

  • Site not named

    Annandale, Virginia

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Neuquén, Argentina

  • Site not named

    San Juan Bautista, Argentina

  • Site not named

    Curitiba, Brazil

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Salvador, Brazil

  • Site not named

    São Paulo, Brazil

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.